Balance Sheets - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Current assets
Cash and cash equivalents	$ 6,451,754	$ 15,998,392
Equity investment in Aytu BioScience, Inc. (Note 3)	268,901
Receivable from Aytu BioScience, Inc.		38,451
Prepaid expenses	638,538	321,574
Prepaid research and development - related party (Note7)	143,802	143,802
Current assets of discontinued operations (Note 8)		12,726,203
Total current assets	7,502,995	29,228,422
Fixed assets, net (Note 2)	8,576,555	9,187,620
Long-term portion of prepaid research and development - related party (Note 7)	251,653	323,553
Deposits	33,856	33,856
Other assets of discontinued operations, net (Note 8)		11,645,142
Total assets	16,365,059	50,418,593
Current liabilities
Accounts payable	1,368,963	1,804,369
Accrued compensation	1,182,955	885,517
Deferred rent	59,579	59,579
Current liabilities of discontinued operations (Note 8)		2,765,648
Total current liabilities	2,611,497	5,515,113
Long-term deferred rent	610,547	629,568
Liabilities of discontinued operations, net (Note 8)		6,346,924
Total liabilities	3,222,044	12,491,605
Commitments and contingencies (Note 4)
Stockholders' equity
Preferred Stock, par value $.0001; 10,000,000 shares authorized; none issued
Common Stock, par value $.0001; 100,000,000 shares authorized; shares issued and outstanding - 52,016,432 (unaudited) in 2016 and 51,998,306 in 2015	5,202	5,200
Additional paid-in capital	158,960,293	170,999,410
Advances to stockholders	(90,640)	(90,640)
Accumulated deficit	(145,731,840)	(133,914,812)
Total Ampio stockholders' equity	13,143,015	36,999,158
Non-controlling interests of discontinued operations		927,830
Total stockholders' equity	13,143,015	37,926,988
Total liabilities and stockholders' equity	$ 16,365,059	$ 50,418,593